ERBB2 and breast cancer: Poor prognostic factors for OS, LRR, or DM determined in patients with breast cancer receiving TM in the present study, namely, moderate-poor differentiation, advanced clinical stages, advanced pathologic TN stages, HER2 positivity, adjuvant RT, and adjuvant chemotherapy (Tables 2–4), are similar to those reported in previous studies (57–61).